Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

soneas.com

Stage

Acquired | Acquired

About Soneas

Soneas is a contract development and manufacturing organization (CDMO) that provides comprehensive services from drug development to manufacturing.

Soneas Headquarters Location

Illatos út 33.

Budapest, H-1097,

Hungary

+36 1 347 5060

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Soneas Patents

Soneas has filed 2 patents.

The 3 most popular patent topics include:

  • Chelating agents
  • Coordination chemistry
  • Coordination compounds
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/9/2016

5/14/2019

Stereochemistry, Amines, Organometallic chemistry, Coordination chemistry, Benzamides

Grant

Application Date

3/9/2016

Grant Date

5/14/2019

Title

Related Topics

Stereochemistry, Amines, Organometallic chemistry, Coordination chemistry, Benzamides

Status

Grant

Latest Soneas News

India Dealbook: Elliott exits Cognizant; Vivimed unit acquires Hungarian firm

May 17, 2018

May 17, 2018 While activist hedge fund Elliott Management has exited technology major Cognizant, pharmaceutical company Vivimed Labs, through its unit UQUIFA, is acquiring Hungarian firm Soneas. Activist hedge fund Elliott Management exits Cognizant US-based activist hedge fund  Elliott Managemen t has exited  Cognizant reaping benefits from a 50 per cent rise in the stock price of the technology major over the last 18 months, according to a report in The Economic Times. Eliott Management is credited with having changed Cognizant’s business strategy a couple of years ago. In 2016, the investment firm disclosed that it had around 4 per cent stake in Cognizant and asked it to begin paying dividends, institute buybacks and shake up its board. Cognizant complied with those requests, beginning a $3.4-billion capital return programme and replacing three members of the board. A Cognizant executive told the newspaper that company’s strategy would not change following Elliott Management’s exit. It was recently reported that Elliot had picked up a small stake in Indian technology giant Wipro Ltd. Vivimed Labs’ unit acquires Hungarian firm Soneas Pharmaceutical company  Vivimed Labs is acquiring Hungarian contract development and manufacturing firm Soneas for an undisclosed amount. Vivimed Labs Spain S.L, the parent of UQUIFA S.A, has signed definitive agreements to facilitate the acquisition of Soneas, a contract development and manufacturing company, focused on the innovator pharma and fine chemical sectors. UQUIFA, the API business of Hyderabad-based Vivimed Labs, acquired the Soneas from Lochlomond and Euroventures which are both based out of Hungary. Also Read:

  • Where is Soneas's headquarters?

    Soneas's headquarters is located at Illatos út 33., Budapest.

  • What is Soneas's latest funding round?

    Soneas's latest funding round is Acquired.

  • Who are the investors of Soneas?

    Investors of Soneas include Uquifa, Euroventures and Lochlomond.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.